Atsena Therapeutics
Sruti Rayaprolu has worked in various roles in the medical field since 2011. Sruti began their career as a Special Projects Associate at the Mayo Clinic in 2011. In 2014, they moved to the University of Florida College of Medicine where they held the roles of Postdoctoral Researcher and Graduate Research Assistant. In 2018, they joined Emory University School of Medicine as a Postdoctoral Fellow. Most recently, in 2022, they were appointed as a Senior Scientist at Atsena Therapeutics.
Sruti Rayaprolu obtained a Bachelor's degree in Biology and Studio Art from the University of North Florida in 2010. Following this, they attended the University of Florida College of Medicine, graduating in 2017 with a Doctor of Philosophy (Ph.D.) in Neuroscience.
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.